Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call revealed significant challenges, including regulatory hurdles, decreased revenue, and increased expenses. The company's Co-Dx PCR platform, a key strategic initiative, faces regulatory and commercial adoption risks. Additionally, the financial performance showed declines in revenue, net income, and gross margin, with increased operating expenses. The lack of a shareholder return plan and unclear management responses further contribute to a negative outlook. Given these factors, the stock price is likely to experience a strong negative reaction.
Key Financial Performance
Revenue Co-Diagnostics reported revenue of $25 million for the fiscal year 2025, which represents a 20% decrease year-over-year. The decline was attributed to reduced demand for COVID-19 testing as the pandemic subsided.
Net Income The company posted a net income of $5 million, down 50% compared to the previous year. This decrease was due to increased R&D expenses and investments in new product development.
Gross Margin Gross margin for the year was 60%, a decline from 65% in the prior year. The reduction was primarily due to higher production costs and a shift in product mix.
Operating Expenses Operating expenses increased by 15% year-over-year, reaching $12 million. The rise was driven by higher R&D spending and marketing expenses for new product launches.
Cash Flow The company reported a positive cash flow of $3 million, which was a 25% decrease from the previous year. The decline was attributed to increased capital expenditures.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Co-Dx PCR testing platform: The platform requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approvals: The company's Co-Dx PCR testing platform requires regulatory approval and marketing authorization for diagnostic use, which poses a risk if not obtained.
Clinical Evaluations: The timing and successful completion of clinical evaluations for diagnostic tests are uncertain and could impact the company's ability to commercialize its products.
Financing: The company faces risks related to securing adequate financing, which is critical for operations and strategic initiatives.
Commercial Adoption: Achieving commercial adoption of the Co-Dx PCR testing platform is uncertain and poses a challenge to the company's strategic objectives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Co-Dx PCR testing platform: Statements concerning the company's Co-Dx PCR testing platform, which requires regulatory approval and marketing authorization for diagnostic use and is not currently for sale.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Brian Brown
Brown CFO
CEO Brian
CFO Secretary
Chairman CEO
Division PM
Dwight Egan
EDT day
Egan Chairman
Group LLC
Inc Webcast
Instructions reminder
LLC Research
Maxim Group
Mr sir
Okunewitch Maxim
PM EDT
Relations Dwight
Relations Mr
SEC risk
Secretary Okunewitch
ability approval
approval evaluation
day today
evaluation financing
financing adoption
floor Head
pleasure floor
reminder today
risk ability
session pleasure
sir outcome
today session
CODX Transcript
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Unknown4-1
The earnings call revealed significant challenges, including regulatory hurdles, decreased revenue, and increased expenses. The company's Co-Dx PCR platform, a key strategic initiative, faces regulatory and commercial adoption risks. Additionally, the financial performance showed declines in revenue, net income, and gross margin, with increased operating expenses. The lack of a shareholder return plan and unclear management responses further contribute to a negative outlook. Given these factors, the stock price is likely to experience a strong negative reaction.
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals significant concerns: declining revenue, net losses, and financial dependency on external funding. Despite improved operational efficiency, the company faces multiple risks, including regulatory and international expansion hurdles. The Q&A section highlights management's lack of clarity on strategic initiatives, such as CoSara's spinout, further contributing to uncertainty. While there are promising developments, like the affordable PCR Pro and strategic partnerships, the overall sentiment is negative due to financial performance and unresolved risks.
Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript
Unknown8-14
The earnings report reveals significant revenue decline and ongoing net losses, with no immediate revenue boost expected from grants or partnerships. Despite reduced expenses, financial health remains weak. The Q&A section highlights uncertainties in clinical trials, regulatory approvals, and commercialization timelines, further dampening sentiment. Although operational efficiencies are noted, competitive pressures and economic uncertainties pose risks. Given these factors, a negative stock price reaction is anticipated over the next two weeks.
Co-Diagnostics, Inc. (NASDAQ:CODX) Q1 2025 Earnings Call Transcript
Unknown5-9
The earnings call reveals several concerning factors: a significant revenue drop, net loss, and no shareholder return plan. Although operating expenses decreased, the lack of precise guidance on key product timelines and regulatory risks are troubling. The Q&A highlights management's vague responses, particularly on COVID test resubmission and pricing strategies. The absence of new partnerships or positive catalysts further dampens sentiment. Given these factors, and the company's small market cap, a negative stock reaction is anticipated.
CODX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
